NGS 종양 치료 시장 규모는 향후 몇 년간 급속히 성장할 것으로 예상됩니다. 예측 기간 동안의 예상 성장은 동반 진단 확대, 종양 유병률 증가, 정부 및 의료 투자 증가, 임상 적용 확대, 표적 치료에 대한 관심 증가에 의해 촉진될 것입니다. 이 기간에 예상되는 주요 동향으로는 AI 및 기계 학습의 통합, 단일 세포 시퀀싱의 발전, 시퀀싱 플랫폼의 개선, 액체 생검 기술의 발전, 고처리량 시퀀싱 플랫폼의 개발 등이 있습니다.
종양의 유병률 증가는 향후 몇 년 동안 NGS 종양 시장의 성장을 촉진할 것으로 예상됩니다. 종양은 비정상적인 세포가 통제할 수 없이 증식하여 신체의 다른 부위로 전이되어 정상적인 신체 기능을 방해하는 질환입니다. 종양의 유병률 증가는 주로 인구 고령화에 기인하며, 종양 발병 위험은 나이가 들면서 증가합니다. NGS 종양은 종양의 상세한 유전적 프로파일링을 통해 조기 발견, 정확한 진단 및 개인 맞춤형 치료를 가능하게 함으로써 증가하는 종양의 부담을 해결하는 데 도움이 됩니다. 미국에 본사를 둔 비영리 단체인 미국 종양 학회(American Cancer Society)에 따르면, 2022년에는 전 세계적으로 약 2,000만 건의 새로운 종양 사례가 보고되어 970만 명이 사망할 것으로 예상됩니다. 주로 인구 증가에 의해 촉진된 세계의 종양 부담은 2050년까지 3,500만 건으로 증가할 것으로 예상됩니다. 따라서 종양의 유병률 증가는 NGS 종양 시장의 확장을 크게 촉진할 것입니다.
NGS 종양 치료 시장 운영 기업들은 순환 종양 DNA 분석을 통해 비침습적, 실시간 종양 검출 및 모니터링을 가능하게 하는 혁신적인 솔루션 개발에 집중하고 있습니다. 액체 생검 연구 검사는 혈액 등 생물학적 체액을 분석해 종양과 관련된 유전적 변이 또는 분자 표지자를 탐지하는 진단 검사입니다. 이를 통해 비침습적 검출 및 모니터링이 가능합니다. 예를 들어, 2024년 8월 미국 기반 NGS 기술 전문 바이오테크 기업인 일루미나(Illumina)는 NovaSeq X 시리즈 사용자를 위한 종양 진단 포트폴리오를 확장했습니다. 이 회사는 새롭게 검증된 고효율 TruSight Oncology 500 (TSO 500 HT)과 업데이트된 TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) 액체 생검 연구 검사를 출시했습니다. 이 고급 분석 키트는 실험실이 조직 및 액체 생검 샘플 모두에 대한 종양 연구 능력을 확장할 수 있도록 지원하며, 시퀀싱 효율성 향상, 실행 시간 단축, NovaSeq X 시리즈에서 처음으로 대규모 샘플 처리 능력을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 NGS 종양 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 NGS 종양 시장 : 성장률 분석
- 세계의 NGS 종양 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 NGS 종양 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 NGS 종양 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 NGS 종양 시장 : 시퀀싱 기술별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 표적 시퀀싱
- 유전체학
- 전사체학
- 에피유전체학
- 세계의 NGS 종양 시장 : 제공별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 플랫폼
- 키트
- 서비스
- 세계의 NGS 종양 시장 : 워크플로우별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 프리 시퀀싱
- 시퀀싱
- 데이터 분석
- 세계의 NGS 종양 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 유전자 스크리닝
- 유전성 유전자 검사
- 조혈 악성 종양
- 고형 종양
- 기타
- 세계의 NGS 종양 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 및 진료소
- 임상연구기관(CRO)
- 학술연구기관
- 제약 및 바이오테크놀러지 기업
- 기타
- 세계의 NGS 종양 시장, 타겟 시퀀싱 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 모든 엑솜 시퀀싱(WES)
- 앰플리콘 기반 시퀀싱
- 혼성화 기반 시퀀싱
- 세계의 NGS 종양 시장 : 유전체학 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 전체 유전체 시퀀싱(WGS)
- 구조적 변이 검출
- 복제 수 변이(CNV) 분석
- 세계의 NGS 종양 시장 : 전사체학 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- RNA 시퀀싱
- 단일 세포 전사체학
- 비 코딩 RNA 분석
- 세계의 NGS 종양 시장 : 에피유전체학 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- DNA 메틸화 시퀀싱
- 크로마틴 면역 침전 시퀀싱
- 히스톤 수식 해석
제7장 지역별, 국가별 분석
- 세계의 NGS 종양 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 NGS 종양 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- NGS 종양 시장 : 경쟁 구도
- NGS 종양 시장 : 기업 프로파일
- Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Agilent Technologies Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Eurofins Scientific SE : 개요, 제품 및 서비스, 전략 및 재무 분석
- Illumina Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Qiagen NV
- Tecan Trading AG
- Myriad Genetics
- Takara Bio Inc.
- Beijing Genomics Institute(BGI)
- Caris Life Sciences
- Foundation Medicine
- Paradigm Diagnostics
- Pacific Bioscience
- Horizon Discovery Group plc
- Creative-Biolabs
- Xcelris Labs Ltd.
- Partek Inc.
- 4baseCare
- SciGenom Labs Pvt. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- NGS 종양 시장(2029년) : 새로운 기회를 제공하는 국가
- NGS 종양 시장(2029년) : 새로운 기회를 제공하는 부문
- NGS 종양 시장(2029년) : 성장 전략
제36장 부록
HBR
Next-generation sequencing (NGS) oncology involves the use of advanced sequencing technologies to examine the genetic composition of cancer cells. It helps identify specific mutations, genetic alterations, and biomarkers that can guide personalized treatment plans, predict responses to therapies, and enhance overall cancer management. NGS oncology facilitates precision medicine, where treatments are tailored to the genetic profile of the tumor.
The primary sequencing technologies in NGS oncology include targeted sequencing, genomics, transcriptomics, and epigenomics. Targeted sequencing is a genomic method that focuses on sequencing specific genes or regions within the genome to detect genetic variations linked to diseases or traits. These technologies are available in platforms, kits, and services. The workflow includes stages such as pre-sequencing, sequencing, and data analysis. They are applied in various areas, including genetic screening, hereditary genetic testing, hematological malignancies, solid tumors, and more. Key end users include hospitals and clinics, clinical research organizations (CROs), academic and research institutions, pharmaceutical and biotechnology companies, and others.
The NGS oncology market research report is one of a series of new reports from The Business Research Company that provides NGS oncology market statistics, including the NGS oncology industry global market size, regional shares, competitors with the NGS oncology market share, detailed NGS oncology market segments, market trends, and opportunities, and any further data you may need to thrive in the NGS oncology industry. This NGS oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The NGS oncology market size has grown rapidly in recent years. It will grow from $17.36 billion in 2024 to $19.39 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to the increasing incidence of cancer, expanding research in cancer genomics, rising public awareness, development of healthcare infrastructure, and growing demand for personalized medicine.
The NGS oncology market size is expected to see rapid growth in the next few years. It will grow to $29.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The projected growth in the forecast period is driven by the expansion of companion diagnostics, rising cancer prevalence, increased government and healthcare investments, broader clinical applications, and growing interest in targeted therapies. Key trends expected in this period include the integration of AI and machine learning, progress in single-cell sequencing, improvements in sequencing platforms, advancements in liquid biopsy technology, and developments in high-throughput sequencing platforms.
The increasing prevalence of cancer is expected to drive the growth of the NGS oncology market in the coming years. Cancer is a condition where abnormal cells grow uncontrollably and spread to other parts of the body, disrupting normal bodily functions. The rising prevalence of cancer is primarily due to aging populations, as the risk of developing cancer increases with age. NGS oncology helps address this growing cancer burden by enabling early detection, accurate diagnosis, and personalized treatment through detailed genetic profiling of tumors. According to the American Cancer Society, a U.S.-based nonprofit organization, in 2022, around 20 million new cancer cases were reported globally, resulting in 9.7 million deaths. Driven mainly by population growth, the global cancer burden is expected to rise to 35 million cases by 2050. Thus, the increasing prevalence of cancer will significantly drive the expansion of the NGS oncology market.
Companies operating in the NGS oncology market are focusing on developing innovative solutions, such as liquid biopsy research assays, to enable non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic test that analyzes biological fluids such as blood to detect genetic mutations or molecular markers linked to cancer, allowing for non-invasive detection and monitoring. For example, in August 2024, Illumina Inc., a U.S.-based biotechnology company specializing in NGS technology, expanded its oncology portfolio for NovaSeq X Series users. The company introduced the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assays. These advanced assays enable laboratories to expand their oncology research capabilities for both tissue and liquid biopsy samples, offering improved sequencing efficiency, reduced run times, and the ability to process larger sample volumes on the NovaSeq X Series for the first time.
In December 2024, Deerfield Management Company, a U.S.-based investment firm, acquired Singular Genomics for an undisclosed amount. This acquisition aims to strengthen Deerfield's portfolio by integrating Singular Genomics' next-generation sequencing and spatial multiomics technologies, advancing research and clinical applications. Singular Genomics is a U.S.-based biotechnology company specializing in NGS and multiomics technologies.
Major players in the NGS oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, and SciGenom Labs Pvt. Ltd.
North America was the largest region in the NGS oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in NGS oncology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the NGS oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The NGS oncology market consists of revenues earned by entities by providing services such as companion diagnostics, liquid biopsy analysis, genetic mutation analysis, bioinformatics, and data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The NGS oncology market also includes sales of target enrichment kits, library preparation kits, data analysis pipelines, bioinformatics software, and tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
NGS Oncology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ngs oncology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ngs oncology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ngs oncology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Sequencing Technology: Targeted Sequencing; Genomics; Transcriptomics; Epigenomics
- 2) By Offering: Platform; Kits; Services
- 3) By Workflow: Pre-Sequencing; Sequencing; Data Analysis
- 4) By Application: Genetic Screening; Hereditary Genetic Testing; Hematological Malignancies; Solid Tumors; Other Applications
- 5) By End User: Hospitals And Clinics; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
- Subsegments:
- 1) By Targeted Sequencing: Whole Exome Sequencing (WES); Amplicon-Based Sequencing; Hybridization-Based Sequencing
- 2) By Genomics: Whole Genome Sequencing (WGS); Structural Variant Detection; Copy Number Variation (CNV) Analysis
- 3) By Transcriptomics: RNA Sequencing; Single-Cell Transcriptomics; Non-coding RNA Analysis
- 4) By Epigenomics: DNA Methylation Sequencing; Chromatin Immunoprecipitation Sequencing; Histone Modification Analysis
- Companies Mentioned: Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Eurofins Scientific SE; Illumina Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. NGS Oncology Market Characteristics
3. NGS Oncology Market Trends And Strategies
4. NGS Oncology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global NGS Oncology Growth Analysis And Strategic Analysis Framework
- 5.1. Global NGS Oncology PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global NGS Oncology Market Growth Rate Analysis
- 5.4. Global NGS Oncology Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global NGS Oncology Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global NGS Oncology Total Addressable Market (TAM)
6. NGS Oncology Market Segmentation
- 6.1. Global NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Targeted Sequencing
- Genomics
- Transcriptomics
- Epigenomics
- 6.2. Global NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Platform
- Kits
- Services
- 6.3. Global NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pre-Sequencing
- Sequencing
- Data Analysis
- 6.4. Global NGS Oncology Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Genetic Screening
- Hereditary Genetic Testing
- Hematological Malignancies
- Solid Tumors
- Other Applications
- 6.5. Global NGS Oncology Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals And Clinics
- Clinical Research Organizations (CROs)
- Academic And Research Institutes
- Pharmaceutical And Biotechnology Companies
- Other End Users
- 6.6. Global NGS Oncology Market, Sub-Segmentation Of Targeted Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Whole Exome Sequencing (WES)
- Amplicon-Based Sequencing
- Hybridization-Based Sequencing
- 6.7. Global NGS Oncology Market, Sub-Segmentation Of Genomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Whole Genome Sequencing (WGS)
- Structural Variant Detection
- Copy Number Variation (CNV) Analysis
- 6.8. Global NGS Oncology Market, Sub-Segmentation Of Transcriptomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- RNA Sequencing
- Single-Cell Transcriptomics
- Non-coding RNA Analysis
- 6.9. Global NGS Oncology Market, Sub-Segmentation Of Epigenomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- DNA Methylation Sequencing
- Chromatin Immunoprecipitation Sequencing
- Histone Modification Analysis
7. NGS Oncology Market Regional And Country Analysis
- 7.1. Global NGS Oncology Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global NGS Oncology Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific NGS Oncology Market
- 8.1. Asia-Pacific NGS Oncology Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China NGS Oncology Market
- 9.1. China NGS Oncology Market Overview
- 9.2. China NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India NGS Oncology Market
- 10.1. India NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan NGS Oncology Market
- 11.1. Japan NGS Oncology Market Overview
- 11.2. Japan NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia NGS Oncology Market
- 12.1. Australia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia NGS Oncology Market
- 13.1. Indonesia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea NGS Oncology Market
- 14.1. South Korea NGS Oncology Market Overview
- 14.2. South Korea NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe NGS Oncology Market
- 15.1. Western Europe NGS Oncology Market Overview
- 15.2. Western Europe NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK NGS Oncology Market
- 16.1. UK NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany NGS Oncology Market
- 17.1. Germany NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France NGS Oncology Market
- 18.1. France NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy NGS Oncology Market
- 19.1. Italy NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain NGS Oncology Market
- 20.1. Spain NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe NGS Oncology Market
- 21.1. Eastern Europe NGS Oncology Market Overview
- 21.2. Eastern Europe NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia NGS Oncology Market
- 22.1. Russia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America NGS Oncology Market
- 23.1. North America NGS Oncology Market Overview
- 23.2. North America NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA NGS Oncology Market
- 24.1. USA NGS Oncology Market Overview
- 24.2. USA NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada NGS Oncology Market
- 25.1. Canada NGS Oncology Market Overview
- 25.2. Canada NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America NGS Oncology Market
- 26.1. South America NGS Oncology Market Overview
- 26.2. South America NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil NGS Oncology Market
- 27.1. Brazil NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East NGS Oncology Market
- 28.1. Middle East NGS Oncology Market Overview
- 28.2. Middle East NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa NGS Oncology Market
- 29.1. Africa NGS Oncology Market Overview
- 29.2. Africa NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. NGS Oncology Market Competitive Landscape And Company Profiles
- 30.1. NGS Oncology Market Competitive Landscape
- 30.2. NGS Oncology Market Company Profiles
- 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
31. NGS Oncology Market Other Major And Innovative Companies
- 31.1. Qiagen N.V.
- 31.2. Tecan Trading AG
- 31.3. Myriad Genetics
- 31.4. Takara Bio Inc.
- 31.5. Beijing Genomics Institute (BGI)
- 31.6. Caris Life Sciences
- 31.7. Foundation Medicine
- 31.8. Paradigm Diagnostics
- 31.9. Pacific Bioscience
- 31.10. Horizon Discovery Group plc
- 31.11. Creative-Biolabs
- 31.12. Xcelris Labs Ltd.
- 31.13. Partek Inc.
- 31.14. 4baseCare
- 31.15. SciGenom Labs Pvt. Ltd.
32. Global NGS Oncology Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The NGS Oncology Market
34. Recent Developments In The NGS Oncology Market
35. NGS Oncology Market High Potential Countries, Segments and Strategies
- 35.1 NGS Oncology Market In 2029 - Countries Offering Most New Opportunities
- 35.2 NGS Oncology Market In 2029 - Segments Offering Most New Opportunities
- 35.3 NGS Oncology Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
